Ophthalmic aspects of erectile dysfunction drugs.
Verit
Ayhan
A
Oguz
Halit
H
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data; D002243:Carbolines / Q000009:adverse effects; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects; D008297:Male; D018917:Optic Neuropathy, Ischemic / Q000139:chemically induced*; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects*; D010879:Piperazines / Q000009:adverse effects; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000009:adverse effects; D000068581:Tadalafil; D014227:Triazines / Q000009:adverse effects; D000069058:Vardenafil Dihydrochloride; D014786:Vision Disorders / Q000139:chemically induced*
D002243:Carbolines; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; D000068581:Tadalafil; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases